# Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

> **NCT02585869** · PHASE2 · COMPLETED · sponsor: **NeuroBo Pharmaceuticals Inc.** · enrollment: 161 (actual)

## Conditions studied

- Hypercholesterolemia
- Hypertriglyceridemia

## Interventions

- **DRUG:** Gemcabene 150 mg
- **DRUG:** Gemcabene 300 mg
- **DRUG:** Gemcabene 600 mg
- **DRUG:** Gemcabene 900 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02585869
- **Lead sponsor:** NeuroBo Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2001-06
- **Final completion:** 2001-06
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585869, "Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02585869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*